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Background: Because of the increased life-expectancy of persons with HIV, the need for age-appropriate colorectal
cancer screening among these patients will increase. We examined rates of colorectal cancer screening among
HIV-infected men aged 50 to 65 years.
Methods: We used Ontario’s administrative databases to identify all men between the ages of 50 and 65 years
who were alive on April 1, 2007, and identified HIV-infected men using a validated case-finding algorithm. We
excluded men with a history of colorectal cancer, anal cancer, inflammatory bowel disease and any colorectal investigation
in the preceding five-years, and used multivariable regression to compare rates of colorectal cancer screening between
men with and without HIV during five years of follow-up.
Results: We identified 743,801 men between the ages of 50 and 65 years, of whom 1,432 (0.19%) were HIV-infected. The
proportions of men with and without HIV who underwent any screening during the 5-year follow up period were 49.1%
(95% CI 46.5% to 51.7%) and 41.4% (95% CI 41.3% to 41.5%), respectively. Compared with HIV-negative men, men with HIV
had lower rates of fecal occult blood testing [adjusted rate ratio (aRR) 0.74; 95% confidence interval (CI) 0.63 to 0.87] and
barium-enema radiography (aRR 0.66; 95% CI 0.39 to 1.12), but higher rates of colonoscopy (aRR 1.24; 95% CI 1.13 to 1.37),
flexible sigmoidoscopy (aRR 1.72; 95% CI 1.28 to 2.30) and rigid sigmoidoscopy (aRR 2.98; 95% CI 2.26 to 3.93).
Conclusion: As with the general population of men aged 50 to 65 years, less than half of the population of men with HIV
received colorectal cancer screening. Strategies are required to improve uptake of this intervention.
Keywords: HIV, Colonoscopy/utilization, Colorectal neoplasms/diagnosis, Population surveillance, Health services
accessibility, MaleBackground
Rates of acquired immunodeficiency syndrome (AIDS)-
associated malignancies such as Kaposi’s sarcoma and
non-Hodgkin’s lymphoma have declined markedly among
persons with human immunodeficiency virus (HIV) infec-
tion in the years following the introduction of combin-
ation antiretroviral therapy [1,2]. However, the incidence
of cancers not traditionally associated with HIV, including
colorectal cancer, has increased more than three-fold in
this population over the same period, such that these non-
AIDS-defining malignancies now account for an increas-
ing proportion of deaths among persons with HIV [2-4].* Correspondence: tantoniou@smh.ca
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unless otherwise stated.In this context, research examining access to and
utilization of services directed towards the prevention
and treatment of cancer is required to optimize the
health of these patients.
Colorectal cancer is the second leading cause of
cancer-related death in North America, with an esti-
mated 9,200 Canadians dying from this disease in 2012
[5]. While the natural history and prognosis of colorectal
cancer in the setting of HIV remains poorly character-
ized, available data suggest that patients with HIV have
more advanced stage disease at presentation relative to
non-HIV infected individuals [6-10]. In light of these
data, an aging cohort of persons with HIV and evidence
that screening for colorectal cancer reduces mortality as-
sociated with this disease, integration of age-appropriate
colorectal cancer screening into the care of patients with
HIV will be increasingly required [11-13]. Although severalral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tilized in HIV-infected relative to non-infected patients,
there are no population-based data examining the utilization
of colorectal cancer screening in persons with HIV [14-18].
We therefore compared rates of colorectal cancer screening
among 50 to 65 year old men living with and without HIV
infection in Ontario, Canada, a setting of universal health
coverage and home to over 40% of Canada’s population of
persons with HIV [19]. We focused our comparisons on
men because women comprise less than 15% of persons
with HIV over the age of 50 in Ontario [20].
Methods
Data sources
We obtained data from Ontario’s administrative health-
care databases, which are available at the Institute for
Clinical Evaluative Sciences through a data sharing agree-
ment with the Ontario Ministry of Health and Long-Term
Care. Specifically, we used the Ontario Health Insurance
Plan database to identify claims submitted by physicians
to the provincial universal health insurance program. We
obtained diagnostic and procedural information on all pa-
tients discharged from hospitals and same-day surgery
units from the Canadian Institute for Health Information
Discharge Abstract Database. We used the Ontario Can-
cer Registry, a registry of all Ontario residents who have
been diagnosed with or died of cancer, to identify individ-
uals with a diagnosis of colorectal cancer. Finally, we used
the Registered Persons Database, a registry of all On-
tario residents eligible for provincial health services, to
identify individual demographic information such as
age and postal code, and the Institute for Clinical
Evaluative Sciences Physician Database to determine
physician specialty. These databases were determinis-
tically linked in an anonymous fashion using encrypted
health card numbers, and are routinely used for population-
based research examining the utilization of colorectal
investigations [21-23].
Study population
We used the Registered Persons Database to identify all
men in Ontario between the ages of 50 to 65 years who
were alive and eligible for health insurance as of the
index date of the study, April 1, 2007. From within this
cohort, we identified men with HIV using a previously
validated case-finding algorithm, the development of
which has been described in detail elsewhere [24]. Briefly,
an algorithm of three physician claims with an Inter-
national Classifications of Diseases, 9th edition (ICD-9)
code for HIV infection (042, 043, 044) within a three year
period achieved a sensitivity and specificity of 96.2% (95%
confidence intervals: 95.2% to 97.9%) and 99.6% (95% con-
fidence interavals: 99.1% to 99.8%), respectively, for the
identification of persons with diagnosed HIV. Because ouradministrative databases do not allow us to distinguish be-
tween diagnostic and screening investigations, we ex-
cluded all men where the likelihood of receiving a
colorectal cancer investigation for diagnostic reasons
was high using an approach similar to that described
in previous studies [22,25]. Specifically, we excluded
men with a diagnosis of colorectal cancer, anal cancer
and inflammatory bowel disease in the five years pre-
ceding the index date, and men who had received any
colorectal investigation (i.e. fecal occult blood test,
barium enema radiography, rigid or flexible sigmoidos-
copy and colonoscopy) in the five years preceding the
index date (see Additional file 1: Table S1 and S2 for
relevant diagnostic and procedure codes). The remaining
individuals approximated a cohort at average risk of colo-
rectal cancer [25].
Outcomes
The primary outcome of the study was the receipt of in-
dividual colorectal cancer screening during the five-year
follow-up period. In Ontario, biennial fecal occult blood
testing is the recommended screening modality for aver-
age risk individuals aged 50 to 74 years, with endoscopic
investigations recommended for higher risk individuals
or as follow-up to positive fecal occult blood tests. All
colorectal screening tests (fecal occult blood testing and
endoscopic tests) are provided at no cost to Ontario res-
idents through the single-payer, government adminis-
tered public health system. In this study, we examined
rates of fecal occult blood testing and endoscopic inves-
tigations in the event that restricting our focus on the
former would underestimate the extent of colorectal
screening. We considered an individual appropriately
screened if they received a fecal occult blood test within
2 years of cohort entry, or any one of a colonoscopy,
flexible or rigid sigmoidoscopy, or barium-enema radiog-
raphy examination within 5 years of cohort entry (see
Additional file 1 for procedural codes). We followed
each person in the cohort for up to five-years from the
index date until the receipt of a colorectal investigation,
death, or end of the study period (March 31, 2012),
whichever occurred first. Consequently, each individual
could only receive one colorectal investigation during
the follow-up period.
Statistical analysis
In our main analysis, we used multivariable Poisson re-
gression analysis to investigate rates of colorectal cancer
screening in men with and without HIV-infection. Ad-
justed rate-ratios comparing screening among men with
and without HIV-infection were derived from models
that included the natural logarithm of the count of each
colorectal investigation as the dependent variable, the nat-
ural logarithm of person-time as an offset, and independent
Table 1 Baseline characteristics
Variable HIV(n = 1,432) No HIV
(n =742,369)
p-value
Mean age (SD) 54.9 (4.3) 56.2 (4.5) <0.001
Rural residence, No. (%) 71 (5.0%) 110,943 (14.9%) <0.001
Gastroenterologist
visit in previous
2 years, No. (%)
82 (5.7%) 14,644 (2.0%) <0.001
Mean number of
physician visits in
previous 2 years (SD)
21.9 (21.3) 9.1 (11.9) <0.001
Number of Aggregated
Diagnosis Groups, No. (%)
<0.001
0 38 (2.7%) 116,677 (15.7%)
1 to 3 370 (25.8%) 271,294 (36.5%)
4 to 7 624 (43.6%) 265,225 (35.7%)
8 to 10 249 (17.4%) 66,737 (9.0%)
>11 151 (10.5%) 22,436 (3.0%)
Number of Resource
Utilization Bands, No. (%)
<0.001
0 38 (2.7%) 116,685 (15.7%)
1 7 (0.5%) 34,908 (4.7%)
2 20 (1.4%) 128,212 (17.3%)
3 698 (48.7%) 366,400 (49.4%)
4 403 (28.1%) 66,170 (8.9%)
5 266 (18.6%) 29,994 (4.0%)
Income Quintile, No. (%)† <0.001
1 (lowest) 452 (31.6%) 144,953 (19.5%)
2 304 (21.2%) 148,317 (20.0%)
3 229 (16.0%) 145,079 (19.5%)
4 189 (13.2%) 147,895 (19.9%)
5 233 (16.3%) 148,757 (20.0%)
Missing 25 (1.7%) 7,368 (1.0%)
†Mean household income of neighborhood.
Aggregated Diagnosis Groups: Measures levels of patient co-morbidity, with
increasing number representing higher level of comorbidity burden.
Resource Utilization Bands: Measures category of expected resource use, from
0 (lowest expected resource use) to 5 (highest expected resource use).
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screening, including age, neighborhood income quintile
based on recent postal code and 2006 Census data, urban
versus rural residence, number of physician visits in the
2 years preceding cohort entry, and whether the individual
had been seen by a gastroenterologist in the 2 years preced-
ing cohort entry. We also used the Johns Hopkins Adjusted
Clinical Groups Case-Mix System to adjust for differences
in comorbidity burden and resource use in the two years
preceding the index date [26]. This system uses diagnostic
information from administrative databases to describe and
predict use of health care resources. In this study, we used
Aggregated Diagnosis Groups (ADGs), which are clusters
of diagnostic codes that are similar in terms of severity and
expected persistence. The number of ADGs ranges from 0
to a maximum of 32, with a higher number reflecting a
higher level of co-morbidity. We also used Resource
Utilization Bands (RUBs), which are aggregations of age-
sex diagnostic groups associated with different levels of ex-
pected resource use, ranging from 0 (lowest expected
health care use) to 5 (highest expected health care use), to
categorize patients based on their expected use of health
care resources. This system has been validated for use in
Canadian populations, and both measures are routinely
used for case-mix adjustment in health services research
[27-29]. In a sensitivity analysis, we replicated these ana-
lyses in a cohort that included men who had undergone a
colorectal cancer investigation in the five years preceding
the index date, as these individuals may exhibit different
health seeking behaviours than men who did not receive an
investigation during this period.
In secondary analyses, we determined predictors for
the receipt of colonoscopy and fecal occult blood testing
in men with HIV only. The variables we included in
these models were age, income quintile, rural or urban
residence, level of co-morbidity reflected by the number
of ADGs and RUBs, number of physician visits in the
2 years preceding cohort entry, and whether the individ-
ual had been seen by a gastroenterologist in the 2 years
preceding cohort entry
All statistical analyses were conducted using SAS ver-
sion 9.3 (SAS institute, Cary, North Carolina, USA).
Ethics approval
We obtained ethics approval for this study from the
Research Ethics Board of Sunnybrook Health Sciences
Centre.
Results
We identified a total of 725,801 men between the ages
of 50 and 65 years who were alive as of April 1, 2007, of
whom 1,432 (0.19%) were HIV-positive. Compared with
men without HIV, men living with HIV were dispropor-
tionately represented in low income neighborhoods, hada greater comorbidity burden as reflected by the number
of ADGs and RUBs, and had more physician visits in the
two years preceding the index date (Table 1).
Overall, 703 (49.1%; 95% confidence interval 46.5% to
51.7%) HIV-infected men received any colorectal investi-
gation during follow-up, compared with 307,567 (41.4%;
95% CI 41.3% to 41.5%) of men without HIV (adjusted
rate ratio 1.15, 95% confidence interval 1.07 to 1.24).
When examined according to individual investigation,
men with HIV had lower rates of fecal occult blood test-
ing (54.3 versus 71.2 per 1000 person years; adjusted rate
ratio 0.74, 95% confidence interval 0.63 to 0.87) and
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son years; adjusted rate ratio 0.66, 95% confidence inter-
val 0.39 to 1.12) relative to men without HIV (Figure 1).
In contrast, compared with men without HIV, men
with HIV had higher rates of flexible sigmoidoscopy
(7.0 versus 3.4 per 1000 person-years; adjusted rate ra-
tio 1.72, 95% confidence interval 1.28 to 2.30), rigid
sigmoidoscopy (7.6 versus 2.0 per 1000 person-years;
adjusted rate ratio 2.98, 95% confidence interval 2.26
to 3.93) and colonoscopy (65.2 versus 47.3 per 1000
person-years; adjusted rate ratio 1.24, 95% confidence
interval 1.13 to 1.37) during the follow-up period (Figure 1).
These estimates were similar when including those men
who had received a colorectal investigation in the preced-
ing five years (Additional file 1: Table S3).
In our secondary analyses examining receipt of colo-
rectal cancer investigations in men with HIV only, 156
(10.9%) and 435 (30.4%) men with HIV underwent either
fecal occult blood testing or colonoscopy, respectively.
Apart from a higher rate of colonoscopy use among men
with a relatively low comorbidity burden (adjusted rate
ratio 1.27, 95% confidence interval 1.01 to 1.61), there
were no statistically significant associations between the
receipt of either of these investigations and patient char-
acteristics (Table 2).
Discussion
In our population-based study, we found that the majority
of men who were eligible for colorectal cancer screeningFigure 1 Adjusted rate ratios for receipt of colorectal investigations ireceived no such testing during five years of follow-up Al-
though our estimates encompass both screening and diag-
nostic testing, the receipt of a colorectal investigation by
only 49% of men with HIV is clearly sub-optimal. This
finding indicates that half of the men with HIV underwent
no evaluation of any type and thus were not screened
for colorectal cancer. Our findings are similar to those
of other studies examining colorectal cancer screening
among persons with HIV. In single-centre studies, the
proportions of persons with HIV aged 50 years and
older who received colorectal cancer screening has
ranged from 46.9% to 55.6% [14-17]. In a large study
using United States Medicaid claims data on benefi-
ciaries in five states, only 35.8% of 22,928 age-eligible
persons with HIV underwent colorectal cancer screen-
ing between 1999 and 2007 [18]. However, these findings
likely underestimate the extent of screening somewhat be-
cause claims for fecal occult blood testing were not exam-
ined in this study [18]. Nonetheless, taken as a whole, the
existing evidence suggests that efforts to improve colorec-
tal cancer screening rates in persons with HIV are needed.
Our findings have important implications for the care
of patients with HIV. Although overall rates of screening
were slightly higher in men with HIV relative to men
without HIV, small studies suggest that colorectal cancer
is diagnosed at a later stage and is associated with
poorer outcomes in patients with HIV relative to non-
HIV-infected patients [6-10]. In addition, several studies
have noted a higher prevalence of adenomatous polypsn men with HIV relative to non-HIV-infected men.
Table 2 Multivariable analysis of predictors of fecal occult
blood testing and colonoscopy in men with HIV





Age 1.03 0.99 to 1.07 1.02 0.99 to 1.04
Income Quintile
1 (reference) 1.00 1.00
2 1.09 0.71 to 1.67 0.92 0.70 to 1.21
3 0.95 0.58 to 1.55 1.03 0.77 to 1.37
4 1.18 0.73 to 1.91 0.83 0.60 to 1.15
5 0.72 0.42 to 1.22 1.13 0.86 to 1.48
Aggregated Diagnosis Groups†
High (>6) 1.00 1.00
Low 0.87 0.58 to 1.30 1.27 1.01 to 1.61
Resource Utilization Bands*
High (4 or 5) 1.00 1.00
Low 0.71 0.47 to 1.06 0.96 0.76 to 1.22
Geographic Residence
Urban 1.00 1.00
Rural 0.88 0.41 to 1.89 0.75 0.45 to 1.24
Gastroenterologist visit
None 1.00 1.00
>1 0.63 0.26 to 1.53 1.25 0.85 to 1.84
Number of physician visits 1.00 0.99 to 1.01 1.00 0.99 to 1.00
†Aggregated Diagnosis Groups: Measures levels of patient co-morbidity, with
increasing number representing higher level of comorbidity burden.
*Resource Utilization Bands: Measures category of expected resource use,
from 0 (lowest expected resource use) to 5 (highest expected
resource use).
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viduals or population estimates of this outcome [30-33],
although such differences have not been observed in all
studies [34]. However, authors of these reports univer-
sally endorse screening for colorectal cancer in persons
with HIV as mechanism for early detection and manage-
ment of colonic neoplasms [30-34]. We also observed
higher rates of colonoscopy utilization among men with
HIV with the lowest level of comorbidity. This disparity
may have important clinical implications for patients
with HIV, since one study noted that 15.7% of all neo-
plastic lesions and 88.9% of advanced neoplastic lesions
in the proximal colon of HIV-infected subjects would
have been missed if flexible sigmoidoscopy had been
used instead of colonoscopy [30]. It is therefore possible
that colonoscopy may be the most appropriate screening
method for these patients, although further research is
required to delineate best colorectal cancer screening
practices in this population.Although we cannot ascertain the reasons for
underutilization of screening in our study, several studies
have identified barriers to the uptake of colorectal cancer
screening in the general population. Among patients,
test-specific barriers related to handling stool and ap-
prehension about bowel preparation, are commonly
cited reasons for avoiding colorectal cancer screening
[35-37]. In addition, failure of a clinician to suggest
screening and lack of knowledge regarding the need
for testing were ranked as the two most important bar-
riers to screening in a survey of 3,357 patients [36].
Other reasons cited by individuals for not being screened
include fear of a positive test result, lack of confidence in
the ability to properly collect specimens for fecal occult
blood testing, inadequate explanation by their provider
and competing health priorities [38-42]. Furthermore, less
education, language barriers and cultural beliefs and atti-
tudes towards screening have been identified as reasons
for lower participation in colorectal cancer screening pro-
grams among some ethnic groups [43,44]. An earlier study
conducted in Ontario using the same datasets as this
study noted a significant socioeconomic gradient in colo-
rectal cancer screening, with individuals in the highest in-
come quintile neighborhoods having higher odds of
receiving any colorectal cancer investigation [25]. Barriers
impeding physician recommendation of colorectal cancer
screening to patients have also been identified, and in-
clude the limited period of time to address multiple
patient comorbidities within a single appointment,
forgetfulness, lack of reminders within the health care sys-
tem and language barriers with non-English speaking
patients [45]. In addition, Ontario physicians appear to
favour colonoscopy over fecal occult blood testing for
colorectal cancer screening, which may influence the
nature of testing recommended [46]. Factors associated
with colorectal cancer screening among persons with
HIV have been investigated in two small studies. In one
study of 115 HIV-positive patients, having a primary care
physician was associated with an over four-fold increase in
the odds of undergoing colorectal cancer screening (odds
ratio 4.59, 95% confidence interval 2.01 to 10.48) [16].
In another study, the most commonly cited barriers to
colorectal cancer screening among 51 patients with
HIV were the precedence of competing health con-
cerns, the time required for testing and fear of the pro-
cedure or preparation [47].
Apart from low overall rates of screening among this
cohort of men, we found that men with HIV had higher
rates of colonoscopy and sigmoidoscopy and lower rates
of barium enema radiography and fecal occult blood
testing relative to non-HIV-infected men. These discrep-
ancies were not explained by differences in comorbidity,
health service utilization, region of residence or neigh-
borhood income quintile. We speculate that the higher
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with HIV reflects a higher likelihood of gastrointestinal
symptomatology and diagnostic investigations among
these men relative to the non-HIV-infected group, a
premise which is supported by previous research. Spe-
cifically, in one retrospective clinic-based study exam-
ining colorectal cancer screening in patients with HIV,
97% of whom were men, 3.8% of colonoscopies and
64.3% of flexible sigmoidoscopies were undertaken for
routine screening, with the remainder being performed
for a clinical indication [14]. The spectrum of clinical
illness which may predispose patients with HIV to
greater utilization of endoscopic testing is broad, and
includes chronic diarrhea and non-specific symptoms
(e.g. rectal bleeding) associated with human papilloma
virus-related anal dysplasia [48,49], both of which occur
with greater frequency in persons with HIV relative to the
general population [50,51]. In addition, men with HIV in
our cohort were more likely to have been seen by a gastro-
enterologist than HIV-negative men, which may also con-
tribute to the greater use of endoscopic investigations
among these patients. Finally, as noted earlier, physicians
in Ontario generally favour colonoscopy over fecal occult
blood testing for colorectal cancer screening [46]. Whether
this influences physician preference when decisions are
made about screening for patients with HIV is unknown
and is a subject for future research.
The main strength of our study is the use of comprehen-
sive administrative databases, thereby providing population-
based estimates of colorectal cancer screening that pertain
to all men aged 50 to 65 years who have been diagnosed
with HIV. To our knowledge, ours is the first population-
based study examining rates of colorectal cancer
screening in these men and addresses some limitations of
earlier studies addressing this question, including lack of
generalizability. However, several limitations of our work
merit emphasis. First, our findings are not generalizable to
the population of women with HIV and men below the
age of 50. This limitation is shared by previous research
examining colorectal cancer screening [14]. In addition,
despite excluding men with a history of colorectal cancer,
inflammatory bowel disease and colorectal investigations
in the five years preceding cohort entry, we could not dis-
criminate between screening and diagnostic testing using
our databases. However, because our estimate includes all
testing performed, our finding that 49% of men with HIV
received any colorectal cancer testing is an upper bound
on the proportion of men screened, reinforcing the
underutilization of colorectal cancer screening in these
patients.
Conclusions
In conclusion, we found that despite universal access to
colorectal cancer screening, receipt of this preventivemodality among men over the age of 50 is suboptimal.
Although overall rates of screening were slightly higher
among men with HIV, interventions are required to fur-
ther optimize uptake of colorectal cancer screening in
these patients. Further research is necessary to under-
stand reasons for the suboptimal uptake of colorectal
cancer screening in persons with HIV determine the inci-
dence of colorectal cancer in this population and ascertain
whether existing screening guidelines are applicable in the
setting of HIV infection.
Additional file
Additional file 1: Table S1. Procedural and diagnostic codes for
colorectal investigations. Table S2. Diagnostic codes for colorectal cancer
and inflammatory bowel disease. Table S3. Adjusted rate ratios for
receipt of colorectal investigations in men with HIV relative to non-HIV-infected
men (including men who had previously received a colorectal investigation in
the 5 years preceding the index date).
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